Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
The present invention provides azetidinyl phenyl, pyridyl, or pyrazinyl carboxamide derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAKs) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
1. A method of inhibiting an activity of JAK1 comprising contacting JAK1 with a compound, which is 4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide, or a pharmaceutically acceptable salt thereof.
2. A method of inhibiting or ameliorating a disorder selected from myelofibrosis, polycythemia vera (PV), essential thrombocythemia (ET), multiple myeloma, pancreatic cancer, breast cancer, lung cancer, colorectal cancer, rheumatoid arthritis, lymphoma, leukemia, cachexia, Castleman's disease, graft versus host disease and allograft rejection in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound, which is 4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide, or a pharmaceutically acceptable salt thereof.
3. The method of claim 2 , wherein the disorder is myelofibrosis.
4. The method of claim 2 , wherein the disorder is polycythemia vera (PV).
5. The method of claim 2 , wherein the disorder is essential thrombocythemia (ET).
6. The method of claim 3 , wherein the myelofibrosis is post polycythemia vera myelofibrosis (Post-PV MF).
7. The method of claim 3 , wherein the myelofibrosis is post essential thrombocythemia myelofibrosis (Post-ET MF).
8. The method of claim 2 , wherein the disorder is multiple myeloma.
9. The method of claim 2 , wherein the disorder is pancreatic cancer.
10. The method of claim 2 , wherein the disorder is breast cancer.
11. The method of claim 2 , wherein the disorder is lung cancer.
12. The method of claim 2 , wherein the disorder is colorectal cancer.
13. The method of claim 2 , wherein the disorder is rheumatoid arthritis.
14. The method of claim 2 , wherein the disorder is lymphoma.
15. The method of claim 2 , wherein the disorder is leukemia.
16. The method of claim 15 , wherein the leukemia is acute myelogenous leukemia.
17. The method of claim 15 , wherein the leukemia is acute lymphoblastic leukemia.
18. The method of claim 15 , wherein the leukemia is chronic myelogenous leukemia (CML).
19. The method of claim 15 , wherein the leukemia is chronic myelomonocytic leukemia (CMML).
20. The method of claim 2 , wherein the disorder is cachexia.
21. The method of claim 20 , wherein the cachexia results from or is associated with cancer.
22. The method of claim 2 , wherein the disorder is Castleman's disease.
23. The method of claim 2 , wherein the disorder is allograft rejection.
24. The method of claim 2 , wherein the disorder is graft versus host disease.